The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 6, 2009, Pages 427-432

  Acikel, Sadik ^a   Yildirir, Aylin ^b   Aydinalp, Alp ^b   Bal, Ugur ^b   Kaynar, Gamze ^b   Ozin, Bulent ^b   Muderrisoglu, Haldun ^b  

^a MINISTRY OF HEALTH   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Aspirin resistance; Non ST elevation myocardial infarction; PFA 100; TIMI risk score

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; COLLAGEN; CREATINE KINASE; TROPONIN I;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY RISK; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ASPIRIN; COMORBIDITY; DRUG RESISTANCE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA;

EID: 69549096615     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832c87b3     Document Type: Article

References (28)

1. Cannon CP, Braunwald E. Unstable angina and non-ST elevation myocardial infarction. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders; 2005. pp. 1243-1279.
2. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100:1593-1601.
3. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447-452.
4. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
5. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al., TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy): Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879-1887.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324:71-86.
8. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 poststroke patients. Thromb Res 1993; 71:397-403.
9. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655. (Pubitemid 34298607)
10. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965. (Pubitemid 36315537)
11. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43:1122-1126. (Pubitemid 38353000)
12. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108:37-42. (Pubitemid 36197660)
13. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107:45-49. (Pubitemid 35284424)
14. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202. (Pubitemid 28180831)
15. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969. (Pubitemid 30681627)
16. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284:835-842. (Pubitemid 30643610)
17. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT investigators. Platelet IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999; 83:1147-1151.
18. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110:1392-1397. (Pubitemid 39238016)
19. Poulsen TS, Jorgensen B, Korsholm L, Bjorn Licht P, Haghfelt T, Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007; 119:555-562. (Pubitemid 46321503)
20. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006; 22:103-110. (Pubitemid 44473559)
21. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167:1593-1599.
22. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6:444-450. (Pubitemid 351280111)
23. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99:14-26. (Pubitemid 351705320)
24. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3003 patients. Thromb Haemost 2008; 99:1129-1131. (Pubitemid 351810502)
25. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829-1843. (Pubitemid 351615246)
26. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124:80-85.
27. Kilanowska J, Favaloro EJ, Lippi G. Aspirin 'responsiveness', 'nonresponsiveness' or 'resistance': a putative role for von Willebrand factor? Blood Coagul Fibrinolysis 2008; 19:823-824.
28. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34:709-733.